CORT:NASDAQ
Corcept Therapeutics Inc
$110.29
arrow_downward
-3.98%(-4.57) 1D
$111.48
arrow_upward
+1.08% (+1.19)bedtimeAfter hours
Closed: Sep 18, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CORT...
Open
$116.80
High
$117.90
Low
$108.41
Mkt. cap
11.92B
Avg. vol.
851.81K
Volume
17.23M
P/E ratio
258.87
52-wk high
$126.38
52-wk low
$28.66
EPS
$0.43
Beta
0.45
Shares outstanding
108.10M
No. of employees
730
Open
$116.80
High
$117.90
Low
$108.41
Mkt. cap
11.92B
Avg. vol.
851.81K
Volume
17.23M
P/E ratio
258.87
52-wk high
$126.38
52-wk low
$28.66
EPS
$0.43
Beta
0.45
Shares outstanding
108.10M
No. of employees
730
News stories
From web sources and news partners
Investing.com
·
16 hours ago
Corcept Therapeutics president Vieira sells $29,842 of stock
Investing.com
·
1 day ago
Corcept’s relacorilant receives EU panel backing for ovarian cancer
Benzinga
·
1 day ago
Here’s How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 10 Years
CarePlus VietNam
·
1 month ago
Corcept Therapeutics (CORT) Declines 2.48% as Shares Test Key Support Zone - Fibonacci Entry Signals
Profile
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD. Wikipedia
About Corcept Therapeutics Inc
CEO-
Employees730
FoundedMay 13, 1998
HeadquartersMenlo Park, California, United States
SectorPharmaceutical industry
Websitecorcept.com